$TEM delivered 😏 • Sales $315M vs Est. $297M • EPS ($0.22) vs Est. ($0.24) • EBITDA ($6M) vs Est. ($8M) • Genomics Revenue: $242M -- up 115% YoY FY25 Guidance • Sales $1.26B vs Est. $1.24B • EBITDA $5M vs Est. $5M Tempus saw significant re-acceleration of their clinical volumes which grew 30% in the quarter -- as they delivered more than 212K NGS tests.
52,6K